Harnessing the Power of CannabinoidsTM
Led by a world class team, BayMedica is developing efficient and scalable biosynthetic biology and synthetic chemistry processes to deliver a portfolio of natural cannabinoids including CBC, CBDV and THCV as well as novel cannabinoid analogs for life science, pharmaceutical, nutraceutical, cosmetic and animal health applications.
The BayMedica Platform
Biosynthesis is a multi-step process where living organisms use enzymes to catalyze the conversion of simple substrates into complex products. Cannabinoids are one class of compounds synthesized by Cannabis, however, the Cannabis sativa plant is an inefficient biological factory for even the most prevalent compounds such as THC and CBD, which comprise only 2-5% of the biomass of the plant. Cannabis is even less efficient at synthesizing the 100+ minor cannabinoids such as CBC, CBN and CBDV that typically comprise less than 0.1% of plant biomass.
The BayMedica platform solves this issue by engineering common yeast to convert sugar into cannabinoids, including common and rare natural varieties, as well as novel cannabinoid analogs of pharmaceutical interest. Our platform produces rare, non-intoxicating, naturally-occurring cannabinoids and novel cannabinoid analogs. We also leverage our experience in synthetic chemistry where applicable. BayMedica cannabinoids have a wide variety of applications in the pharmaceutical, cosmetic, consumer and animal health industries.
.
BayMedica Products
.
Prodiol®
Our Prodiol family of natural pharmaceutical-grade, cannabinoids will be available as individual and custom formulations for inclusion into consumer products.
.
PurediolTM
Our Purediol family of products feature 95+% pure, ultra-rare, pharmaceutical-grade cannabinoids and novel cannabinoid analogs for pharmaceutical, life-science, research and testing applications.
Our Team
Shane Johnson, MD
Co-Founder, President & CEO
Dr. Johnson is co-founder of a Nevada cannabis cultivator and manufacturer, with extensive experience in strategy and startup management. He holds a BS in neuroscience from Brown University and an MD from Stanford University.
Philip Barr, PhD
Co-Founder, Chief Scientific Officer
Dr. Barr is an expert in polyketide biosynthesis in yeast (cannabinoids are members of the polyketide family) with over 50 patents, 200 manuscripts, and multiple commercial products. He holds a PhD in organic chemistry with over 30 years industry experience.
Charles Marlowe, PhD
Co-Founder, Director of Chemistry
Dr. Marlowe has 25 patents issued and over 30 publications. He has been instrumental in developing small molecule therapeutics. He holds a PhD in organic chemistry from UC Berkeley.
Dave Kent
VP Corporate Development
Jim Kealey, PhD
VP Research & Development
Dr. Kealey has extensive experience in synthetic biology and polyketide synthesis. He has managed large teams and holds a PhD in pharmaceutical chemistry from UCSF.
Chris Meiering, PhD
VP - Commercialization
Dr. Meiering holds a PhD in microbiology from the University of Washington and has over 20 years experience in the companion animal industry.
Jianping Sun, PhD
Director of Molecular Biology
Dr. Sun earned a PhD in biochemistry and molecular biology from USTC – China. She is experienced in fermentation, metabolic engineering and systems biology.